Showing results (271-280 of 365) with videos related to

Sort By:
Pageof 37
Breast (Edinburgh, Scotland)|November 23, 2021
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)Jae Sik Kim, Kyubo Kim, Wonguen Jung, et al.
The Korean Journal of Internal Medicine|February 3, 2005
Use of complementary and alternative medicine among Korean cancer patientsMin Jae Kim, Sang Dae Lee, Duck Ryung Kim, et al.
JAMA Network Open|November 15, 2023
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialMasato Takahashi, Javier Cortés, Rebecca Dent, et al.
Frontiers in Oncology|March 25, 2026
Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical managementYeon Hee Park, Soo Chin Lee, Christian F Singer, et al.
Frontiers in Oncology|July 8, 2025
Part I: consensus statements and expert recommendations for HER2-negative early breast cancer in the Asia-Pacific region: diagnosis and risk assessmentSoo Chin Lee, Yeon Hee Park, Christian F Singer, et al.
Scientific Reports|March 16, 2019
Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicatorBo Young Oh, Hyun-Tae Shin, Jae Won Yun, et al.
NPJ Breast Cancer|September 12, 2024
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBCSeock-Ah Im, Javier Cortes, David W Cescon, et al.
Journal of Breast Cancer|November 20, 2023
Incidence of and Influencing Factors for Arm Lymphedema After Salvage Treatment for an Isolated Locoregional Recurrence of Breast CancerNalee Kim, Haeyoung Kim, Ji Hye Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Pageof 37